Successful Shortening of Tuberculosis Treatment Using Adjuvant Host-Directed Therapy with FDA-Approved Phosphodiesterase Inhibitors in the Mouse Model by Maiga, Mamoudou et al.
Successful Shortening of Tuberculosis Treatment Using
Adjuvant Host-Directed Therapy with FDA-Approved
Phosphodiesterase Inhibitors in the Mouse Model
Mamoudou Maiga
1., Nisheeth Agarwal






1, William R. Bishai
1,3,4*
1Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America, 2Vaccine and Infectious Disease
Research Center, Translational Health Science and Technology Institute, Gurgaon, India, 3KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), Durban,
South Africa, 4Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America
Abstract
Global control of tuberculosis (TB), an infectious disease that claims nearly 2 million lives annually, is hindered by the long
duration of chemotherapy required for curative treatment. Lack of adherence to this intense treatment regimen leads to
poor patient outcomes, development of new or additional drug resistance, and continued spread of M.tb. within
communities. Hence, shortening the duration of TB therapy could increase drug adherence and cure in TB patients. Here, we
report that addition of the United Stated Food and Drug Administration-approved phosphodiesterase inhibitors (PDE-Is)
cilostazol and sildenafil to the standard TB treatment regimen reduces tissue pathology, leads to faster bacterial clearance
and shortens the time to lung sterilization by one month, compared to standard treatment alone, in a murine model of TB.
Our data suggest that these PDE-Is could be repurposed for use as adjunctive drugs to shorten TB treatment in humans.
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Introduction
Tuberculosis (TB) is one of the oldest infectious diseases known
to man, and its causative agent, the bacillus Mycobacterium
tuberculosis (M.tb.) continues to plague the human population in
the twenty-first century. The most recent World Health Organi-
zation (WHO) estimates of the global burden of TB are staggering:
in 2009, there were 9.4 million incident and 14 million prevalent
cases of active TB, with 1.6 million deaths attributable to this
disease [1]. Even more alarming is the announcement by the
WHO that almost 300,000 of these TB cases were associated with
multi- and extensively drug resistant (MDR and XDR, respec-
tively) strains of M.tb. TB takes this global toll despite the
availability of effective chemotherapy regimens, which in part is
due to the extensive length of treatment necessary for cure: six to
nine months of continuous drug administration. Incomplete
adherence to treatment regimens sets the stage for their failure,
contributing both to the continued spread of M.tb. throughout
communities, as well as to the development of drug-resistant
bacilli. Thus, development of a curative TB chemotherapy
regimen of shorter duration could have an enormous positive
impact on TB control around the globe.
TB disease is characterized by an excessive immune response by
the host, leading to severe tissue destruction in the lungs. This
destructive process is necessary to ensure bacterial spread, as
penetration into damaged airways allows for aerosol transmission
of the bacilli. It is becoming increasingly evident that the immune
pathology observed in TB patients is not solely an inappropriate
host response, but rather represents a precarious balance of both
host- and bacteria-induced signaling events [2,3]. Drugs that
manipulate this host-pathogen relationship via modulation of the
host response to M.tb. infection thus represent a large resource of
adjunctive therapy options that could help to improve bacterial
clearance in TB patients.
The nucleotide 39,5 9-cyclic adenosine monophosphate (cAMP)
is a highly conserved second messenger signaling molecule
involved in the regulation of many cellular processes, both for
eukaryotic and prokaryotic systems [4–6]. The concentration of
cAMP within a cell is determined by the activity of two types of
enzymes: adenylate cyclases, which synthesize cAMP, and
phosphodiesterases (PDEs), which break down the cyclic nucleo-
tide [7]. Recent work in our laboratory has demonstrated that
M.tb. can directly manipulate cAMP signaling pathways within
infected host macrophages, and that this mycobacterial subversion
of eukaryotic cAMP signaling influences bacterial survival in mice
[2]. Hence, the cAMP-mediated signaling pathways of the host cell
represent a network which, during an M.tb. infection, could be
targeted with modulatory drugs to reduce bacterial survival.
In mammals, up to 11 classes of PDEs have been identified
based on sequence and structure similarity, substrate specificity
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logic inhibitors are available for PDE types I–V [8]. PDE types
I–III can hydrolyze both cAMP and cyclic guanosine mono-
phosphate (cGMP), but with variable efficiency, while type IV
and type V PDEs specifically hydrolyze cAMP and cGMP,
respectively. In addition to differing substrate specificities, each
PDE type has unique expression and localization profiles. For
example, type III PDEs are prominent in macrophages,
endothelial cells, platelets and airway smooth muscle cells, while
type V PDEs are expressed in the vascular smooth muscle of
pulmonary arteries and veins and bronchial blood vessels, as well
as in airway smooth muscle cells [9]. PDE inhibitors (PDE-Is)
can thus be utilized as tools to investigate the role of these PDEs
during M.tb. infection.
In this study, we examined the influence of PDEs in mouse
model systems of TB. Specifically, we evaluated the impact of two
Food & Drug Administration- (FDA-) approved PDE i(PDE-Is,
cilostazol (a type III PDE-I) and sildenafil (a type V PDE-I), on
bacterial survival and disease pathology in murine TB models.
Our data indicate that administration of PDE-Is to M.tb.-infected
mice results in decreased bacterial burden and overall pathology,
and that the addition of PDE-Is to the standard treatment
regimen shortens the time to bacterial clearance. Our data
suggest that the repurposing of existing FDA-approved PDE-Is
for adjunctive TB chemotherapy could shorten treatment
duration in TB patients, which would significantly impact in
the global struggle against TB.
Results
Evaluation of PDE-Is during M.tb. infection of monocytic
cells
Previous work in our laboratory and by others has shown that
mycobacterial infection of macrophages increases intracellular
cAMP [2,10,11]. In an attempt to modulate intramacrophage
cAMP levels, we administered PDE-Is to M.tb.-infected THP-1
human macrophage-like cells and subsequently measured intra-
cellular cAMP concentrations. M.tb. infection produced approx-
imately a 4-fold burst in intramacrophage cAMP levels, compared
to uninfected cells (Fig. 1). Exposure of the infected cells to
100 mM of the type V PDE-I (PDE5-I) MBM (4-{[39,49-
(Methylenedioxy)benzyl]amino}-6-methoxyquinazoline) increased
the intracellular cAMP concentration by an additional 2.2-fold
(p,0.0001, Friedman test), and exposure of the cells to the type III
PDE-I (PDE3-I) trequinsin resulted in a nearly 8-fold additional
increase in intracellular cAMP levels (p,0.0001, Friedman test).
These results indicated that PDE3- and PDE5-Is could modulate
the intramacrophage cAMP dynamic during M.tb. infection.
MBM and trequinsin are cell biology reagents limited for use in
the laboratory; however, the PDE3-I cilostazol and the PDE5-I
sildenafil are FDA-approved drugs currently used primarily for the
treatment of intermittent claudication and erectile dysfunction,
respectively. Thus, we utilized these clinically relevant drugs to
investigate the disease-modulating effects of PDE-Is in murine
models of TB.
Analysis of PDE-I monotherapy in M.tb.-infected BALB/c
mice
To evaluate if administration of cilostazol or sildenafil altered
the course of TB in mice, we performed a time-to-death
experiment. Six groups of 10 BALB/c mice were infected by
aerosol with a relatively high dose of M.tb. (3.6 log10 colony
forming units [CFU] implanted, as determined day 1 post-
infection). In this model system, mice are infected with a relatively
high inoculum (.3.5 log10CFU), which will cause untreated mice
to die within the first month, allowing for the observation of
differences in time-to-death. Drug administration was initiated the
day after infection with the treatment groups as follows: cilostazol
at 10 mg/kg (C10) and 30 mg/kg (C30); sildenafil at 10 mg/kg
(S10); isoniazid (INH) at 1 mg/kg (INH1) and 25 mg/kg (INH25)
as positive controls, and phosphate buffered saline (sham) as the
negative control. The drugs were administered daily (5 days/week)
by oral gavage for 45 days, and the time to death (post-infection) of
each mouse was recorded. As expected, most of the sham-treated
mice died within 30 days, and none of the INH-treated mice died
during the experiment (Fig. 2, A). Mice receiving C10 experienced
similar time-to-death as the sham-treated mice, while the S10-
treated mice experienced increased survival relative to the sham-
treated mice (Kaplan-Meier p values of 0.04 and 0.005,
respectively). Thus, these data suggested that treatment with
PDE-Is could increase mice survival following high-dose aerosol
infection with M.tb.
To examine the impact of PDE-I administration on bacterial
burden and overall pathology, BALB/c mice were infected with
M.tb. via the aerosol route resulting in an implantation of 3.1 log10
colony forming units (CFUs) in the lungs (determined on day 1
post-infection). In this model system, mice are infected with a
lower inoculum than in the time-to-death model (,3.5 log10CFU)
in order for the sham-treated mice to survive throughout the
length of the experiment, allowing for CFU comparisons to this
critical control group. PDE-I administration was initiated on the
first day post-infection. S10 and C10, as well as a saline control
(sham) were administered daily (5 days/week) by oral gavage.
During the first two weeks of treatment, mice receiving either of
the PDE-Is did not exhibit different lung or spleen CFU counts
than the sham-treated mice (Fig. 2, B and C). However, after 28
days of treatment, less CFU counts were measured in the lungs
and spleens of the C10-treated mice than in sham-treated mice
(p=0.01 for both lungs and spleens CFUs, Friedman test). This
decrease in bacterial burden was associated with a concomitant
increase in body weight (Fig. 2, D). These data further indicated
that PDE-I administration confers a therapeutic benefit in the
tuberculous mouse.
Figure 1. Intracellular cAMP levels increase within M.tb.-
infected THP-1 human monocytic cells upon exposure to
PDE-Is. The treated infected cells received 100 uM of PDE inhibitors
(PDE-I 3, and 5 class) for 2 h followed by infection. UI: uninfected cells;
the PDE5-I was 4-{[39,49-(Methylenedioxy)benzyl]amino}-6-methoxyqui-
nazoline (MBM); and the PDE3-I was trequinsin. Results shown (mean
and SD) represent two biological replicates, each with 2 technical
replicates.
doi:10.1371/journal.pone.0030749.g001
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mouse model of TB
C3HeB/FeJ mice develop well-defined lung granulomas with
central caseous necrosis in response to M.tb. infection [12]. Because
the immune response in this model system generates a granuloma-
tous disease in the mouse, we utilized C3HeB/FeJ mice to analyze
the immunomodulatory effects of cilostazol and sildenafil, with the
rationale being that immunomodulatory changes would be more
pronounced within this model system. Mice were exposed to M.tb.
by aerosol with a day 1 implantation of 3.67 log10CFU, and
treatment was initiated the day following infection. C10 and S10
were administered daily (5 days/week) to both infected and
uninfected C3HeB/FeJ mice. In this model system, statistically
significant differences in lung CFU counts were not observed at day
3, 10, or 25 post-infection (Figure S1). However, administration of
C10 and S10 resulted in decreased levels of tumor necrosis factor a
(TNF-a) and interferonc (IFN-c) and increasedlevels ofinterleukin-
(IL-)10 and IL-17 in mouse lung homogenates, relative to the levels
in infected, untreated mice (Fig. 3). Uninfected mice treated with
C10 or S10 did not exhibit altered cytokine profiles relative to
uninfected, untreated mice (data not shown). Thus, these data
suggest that cilostazol and sildenafil can modulate at least the Th1
balance in mouse granulomatous TB.
Addition of PDE-Is to the standard TB chemotherapy
regimen
Our analyses of cilostazol and sildenafil indicated that these
PDE-Is do not harm the tuberculous mouse, and in fact may
provide a benefit to infected mice in our model systems. Thus,
these data generated from PDE-I monotherapy experiments
prompted us to analyze the effect of cilostazol and sildenafil when
Figure 2. Administration of PDE-I monotherapy to M.tb.-infected mice shows therapeutic benefits by several parameters. (A) Time-to-
death analysis; BALB/c mice infected with 3.6 log10CFU M.tb. were treated daily by oral gavage (starting the day after infection) with 10 or 30 mg/kg of
cilostazol (C) or sildenafil (S). Isoniazid at 1 or 25 mg/kg (INH1 or INH25 respectively) and sham (PBS) were used as positive and negative controls,
respectively. (B–D) BALB/c mice infected with 3.1 log10CFU M.tb. were treated daily by oral gavage (starting the day after infection) with 10 mg/kg
cilostazol (C10), sildenafil (S10) or sham. At day 28 post-infection, lung CFU counts (B), spleen CFU counts (C) and body weight (D) were determined.
doi:10.1371/journal.pone.0030749.g002
Figure 3. Cytokines profile of PDE-I monotherapy of C3HeB/FeJ
infected mice. The administration of cilostazol and sildenafil decreases
proinflammatory cytokine levels in the lungs of M.tb.-infected mice.
C3HeB/FeJ mice infected with 3.67 log10CFU M.tb. were treated daily by
oral gavage (starting the day after infection) with 10 mg/kg cilostazol
(C10) or sildenafil (S10). At 25 days post-infection, lungs were
homogenized, and the concentrations of TNF-a, IFG-c, GM-CSF, IL-10
and IL17 were determined.
doi:10.1371/journal.pone.0030749.g003
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regimen. We analyzed the bactericidal and sterilizing value of the
addition of C10, S10 and C10+S10 to the standard 6 months
short-course drug regimen, which is 2 months of treatment with
rifampin (R), isoniazid (H) and pyrazinamide (Z), followed by 4
months of treatment with R and H. For this experiment, BALB/c
mice were infected via aerosol with an implantation of 3.97
log10CFU (determined day 1 post-infection) (Fig. 4, A). Admin-
istration of drugs was initiated 14 days post-infection, when the
lung bacterial load had reached 7.8 log10CFU. All untreated mice
became moribund within 21 days of infection, and the mice, which
survived to day 28 post-infection, had an average of 8.02
log10CFU in their lungs. At 28 days of treatment, mice with
regimens containing adjunctive cilostazol (C10 or C10+S10) began
to exhibit decreased bacterial lung burden relative to mice
receiving the standard therapy alone (Fig. 4, A). Furthermore,
the cilostazol-containing regimens decreased the time to lung
sterilization by nearly 1 month, compared to mice receiving
standard therapy; at 112 days of treatment, no CFUs were
demonstrated from the lungs of mice receiving the standard
therapy plus C10 or C10+S10, while the lungs of mice receiving
standard (SD) therapy alone or with S10 had bacterial loads of
0.18 and 0.12 log10CFU, respectively. This decrease in bacillary
load in the mice receiving cilostazol was associated with fewer lung
lesions (18 for SD alone, 10 for SD+C10, 13 for SD+S10 and 14
for SD+S10+C10, P=0.49) at day 112 of treatment (Fig. 4, B).
Hence, these data indicate that the addition of C10 or C10 plus
S10 as adjunctive drugs to the current TB treatment regimen
could reduce the duration of treatment necessary to achieve
bacterial clearance.
To analyze the effect of the PDE-Is on relapse following
completion of treatment, ten mice from each group were
maintained for an additional 4 months following termination of
chemotherapy. At the end of this 4 months period, the lungs from
all of the mice treated with standard therapy remained culture-
negative, as did the lungs from all mice treated with adjunctive
PDE-Is (Table 1). These data indicate that, in addition to
decreasing the time to sterilization, incorporation of C10 into
the standard regimen did not increase the likelihood of relapse
during the four months following the end of therapy.
Cilostazol does not reduce the efficacy of rifampin
One complication in the development of new TB drug regimens
is that many compounds have negative pharmacokinetic interac-
tions with the first-line drug rifampin. Although our data do not
suggest or support that a drug-drug interaction between cilostazol
and rifampin (R) occurs, we felt it would be prudent to test for this
specifically. BALB/c mice were infected by aerosol with 3.6
log10CFU. On the day following infection, mice were treated with
either C10, C30, R10, C10+R10 or C30+R10. The addition of
cilostazol at either concentration to rifampin did not impact
rifampin activity after 14 and 28 days of treatment (Fig. 5).
Taken together, our data indicate that cilostazol can safely be
added to the standard short-course TB chemotherapy regimen,
and that the addition of cilostazol decreases the duration of
treatment necessary to achieve bacterial clearance in the lungs.
Discussion
In this communication, we have presented data suggesting that
the PDE3-I cilostazol, an FDA-approved drug used for treatment
of claudication, should be investigated for use as a treatment-
shortening adjunctive drug to the standard TB short-course
chemotherapy regimen. Using two different mouse models of TB,
we have shown that administration of cilostazol provides a
therapeutic effect for tuberculous mice when administered as
monotherapy (Figs. 2, 3). Importantly, we have shown that
addition of cilostazol to the standard 6 months short-course TB
drug regimen resulted in sterilization of the mouse lungs one
month earlier than standard treatment alone (Fig. 4, Table 1).
The duration of current TB drug regimens is widely
acknowledged as contributing to treatment failures, and such
failures are associated with the development of bacterial drug
resistance and continued transmission of M.tb. [13–15]. Hence,
shortening the length of treatment has the potential to improve
treatment adherence and bacterial clearance, while reducing M.tb.
transmission and the development of drug resistant organisms.
Thus, the treatment-shortening potential of cilostazol could
significantly contribute to TB control worldwide.
The use of adjuvant immunomodulatory therapy for the
treatment of TB has been considered for more than a decade. In
2007, the WHO published a report on immunotherapeutic
interventions for TB and concluded that adjunctive immuno-
therapy, in addition to standard chemotherapy, has the potential
to shorten TB treatment duration, thereby improving the
outcome of TB patients [16]. The conclusions of this report
resulted in a WHO recommendation to fast track studies of
immunomodulatory drugs in TB treatment. However, the few
studies of adjuvant immunotherapy for TB that have been
described report mixed outcomes, with multiple side effects
associated with long-term use [17]. In contrast to immunomod-
ulatory treatments such as prednisolone, thalidomide analogs and
etanercept, cilostazol is well-tolerated by the host and is safe for
long-term use in patients [18,19]. The roles of TNF-a and the T
cell response in TB have been largely debated. Immunomodu-
latory agents that inhibit TNF-a have been associated with both
positive and adverse outcomes in TB patients [17,20,21]. While
this topic remains controversial, it is becoming increasingly
evident that it is the balance of TNF-a and other cytokines that
influences the outcome of TB [22]. Our data indicate that the
addition of cilostazol to the standard TB treatment regimen
reduces TNF-a levels in mouse lungs, compared to untreated
mice (Fig. 3), and that this decrease in TNF-a is not associated
with any adverse effects on disease parameters within mice.
Hence, our data suggest that the addition of cilostazol to standard
TB chemotherapy can modulate immune signaling to enhance
the host’s ability to fight M.tb. infection.
Our finding that administration of cilostazol leads to decreased
TNF-a levels is in agreement with results from several mechanistic
studies of cilostazol. Hattori and colleagues have demonstrated
that cilostazol inhibits TNF-a-induced nuclear factor-kB (NF-kB)
activation in a dose dependent manner; this group also reported
that cilostazol attenuated the TNF-a-induced gene expression of
proinflammatory and cell adhesion molecules within THP-1
human monocytic cells [23]. Similar findings have been reported
for PDE3-I-induced inhibition of TNF-a and NF-kB-dependent
gene expression in rat vascular smooth muscle cells [24,25].
Mendes and colleagues have shown that cilostazol administration
dose-dependently decreases TNF-a levels in a mouse model of
intraperitoneal adhesion [26]. Thus, the findings of these
researchers support our data and suggest a possible TNF-a/NF-
kB mechanism of cilostazol action in our tuberculosis model
systems.
Sildenafil and Cilostazol have shown divergence of mechanism.
Sildenafil (S10) prolonged the time to death of mice, decreased the
level of TNF-a but did not impact the CFUs both in either mono-
or multidrug regimens. This divergence may be explained by the
differences in the mechanisms of action and the target of PDEs.
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hydrolyses cAMP and PDE3 both cAMP and cGMP [27]. PDE3
is prominent in macrophages, endothelial cells, platelets and
airway smooth muscle cells, while PDE5 is expressed in pulmonary
vascular smooth muscle of pulmonary arteries and veins, bronchial
blood vessels and airway smooth muscle. PDE4 is expressed more
in the neutrophils, eosinophils, macrophages and endothelial cells
[9].
Figure 4. Addition of PDE-Is to standard TB therapy. The addition of PDE-Is to standard TB therapy reduces bacterial load, lung pathology and
time to lung sterilization, and does not negatively interact with rifampin in M.tb.-infected mice. BALB/c mice were infected with 3.97 log10CFU M.tb
and treatment was started 14 days post-infection. The mice were treated daily by oral gavage with standard therapy (SD, which is 2 months 10 mg/kg
rifampin (R), 25 mg/kg isoniazid H), and 150 mg/kg pyrazinamide (Z), followed by 4 months of R and H), SD plus 10 mg/kg sildenafil (S10), cilostazol
(C10) or both (CS10). (A) CFU counts in mouse lungs. (B) Histopathology analyses of mouse lungs (hematoxylin and eosin stained lung sections).
doi:10.1371/journal.pone.0030749.g004
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infected THP-1 cells using the laboratory/cell biology inhibitors
trequinsin (PDE3-I) and MBM (PDE5-I). Addition of these
chemicals to cell culture media resulted in decreased intracellular
cAMP levels in the infected cells (Fig. 1), thus indicating that the
host-pathogen infection balance could be altered in the presence of
these PDE-Is. While further cell-based characterization of this
observation will certainly reveal critical cell biology effects of these
inhibitors, our interest was to examine their in vivo potential to
influence the host-pathogen relationship. Thus, we shifted our
studies directly into mouse experiments (rather than first stepping
up to a primary cell culture model), as we felt this was a more
representative model system to in which to examine the influence
of PDE-Is on the host-pathogen relationship. Because FDA-
approved PDE3-I (cilostazol) and PDE5-I (sildenafil) drugs were
available, we utilized these compounds four our in vivo experi-
ments, with the rationale being that these same compounds could
be tested in humans, should the data suggest a positive effect and a
lack of drug-drug interactions. However, the effects of cilostazol
and sildenafil in the cell culture model have yet to be examined.
The PDE-I activity of cilostazol and sildenafil is accompanied by
vasodilation, and hence it is possible that this latter activity could be
important in the sterilizing role of these drugs in TB, as it has been
demonstrated that microthrombi develop around mycobacterial
lunglesionsinarabbitmodelofTB[27].Whileourstudydesigndid
not specifically address the role of vasodilation in TB treatment
outcome, our data do not suggest that this is the mechanism of
action of cilostazol, as treatment with sildenafil, which also has
vasodilatory properties, was not associated with a decreased time to
lung sterilization in infected mice. Thus, our data indicate that it is
the specific PDE3-I activity of cilostazol that contributes to
enhancement of standard TB therapy.
Recently, Koo and colleagues reported that use of the PDE4-I
thalidomide analog CC-3052 (administered by oral gavage) in
combination with isoniazid (delivered ad libitum in drinking water)
resulted in a significant decrease in lung CFU counts and lung
pathology in a mouse model of TB; they further demonstrated that
administration of CC-3052 was associated with decreased tnf-a gene
expression [28]. Subsequently, this group also reported similar
findings in a rabbit pulmonary TB model [29,30]. These exciting
findings support the concept that PDE-Is can influence the host
responsetoM.tb.Whilewedidnotexamine inhibition ofPDE4-Isin
this study, we have shown that the addition of a PDE3-I and a
PDE5-I to the standard 6-month TB chemotherapy regimen
decreased the time to bacterial clearance in the lungs of infected
mice. Thus, similar patterns were observed using type III, IV and V
PDE-Is, and our data suggest that an FDA-approved PDE4-I could
also be examined in a full chemotherapy model of TB.
In summary, we have demonstrated that the addition of the
PDE3-I cilostazol to the standard TB chemotherapy regimen leads
to lung sterilization one month earlier than treatment with
standard therapy alone in a murine model of TB. This decreased
time to bacterial clearance was associated with improved health
measures, both on gross and histopathologic disease parameters.
Shortening the duration of TB treatment is widely acknowledged
as a mechanism for improving TB control and limiting the
development of drug resistant M.tb. [13–15]. Cilostazol is currently
an FDA-approved drug for the treatment of intermittent
claudication and is safe for prolonged use in humans, as opposed
to PDE4-Is, which are known to be associated with side effects
[31]. Hence, cilostazol represents an existing available drug, which
may be repurposed as an adjunctive agent for the treatment of TB.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
procedures described in this communication have been approved
by the Johns Hopkins University Animal Care and Use
Committee.
Animals
Approximately 6 week-old female mice were used for all
experiments. BALB/c mice were obtained from Charles River
Laboratories (Wilmington, MA, USA), and C3HeB/FeJ mice were
purchased from The Jackson Laboratory (Bar Harbor, ME, USA).
Mice were maintained in an animal biosafety level 3 laboratory at
all times.
Bacterial and cell culture stocks
Mycobacterium tuberculosis strains H37Rv and CDC1551were
obtained from the Johns Hopkins Center for Tuberculosis
Table 1. Proportion of mice with no detectable CFUs during
TB standard therapy with and without PDE-I.
Days of treatment SD SD+SS D +CS D +CS
56 0/5 0/5 0/5 2/5
84 1/5 0/5 3/5 1/5
112 2/5 3/5 5/5 5/5
140 5/5 5/5 5/5 5/5
168 5/5 5/5 5/5 5/5
168+112 10/10 10/10 10/10 10/10
The proportions of mice with no detectable CFUs were determined by
homogenizing and plating the entire lungs from 56 to 168 days of treatment.
Treatment was terminated after 168 days, and groups of mice were kept for an
additional 4 months (168+112). Shading indicates lung sterilization in all mice in
the group. SD: standard drug therapy (see Fig. 4 legend for details); S: 10 mg/kg
sildenafil; C: 10 mg/kg cilostazol; CS: 10 mg/kg each of sildenafil and cilostazol.
doi:10.1371/journal.pone.0030749.t001
Figure 5. Interaction of PDE-Is with Rifampin. BALB/c mice were
infected with 3.6 log10CFU M.tb. and were treated daily by oral gavage
(starting the day after infection) with 10 or 30 mg/kg cilostazol (C10 and
C30, respectively), 10 mg/kg rifampin (R10), C10 plus R10, or C30 plus
R10. Lung CFU counts were determined on days 14 and 28 post-
infection.
doi:10.1371/journal.pone.0030749.g005
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were grown in 7H9 Middlebrook liquid medium supplemented
with oleic acid-albumin-dextrose-catalase, 0.5% glycerol and
0.05% Tween-80. THP-1 cells were obtained from ATCC (TIB-
202
TM), and were grown in RPMI medium supplemented with L-
glutamine and fetal bovine serum.
Aerosol infection procedure
Aerosol infections were performed with bacterial cultures diluted
appropriately to achieve the desired inoculum using the Glas-col
Inhalation Exposure System, per the manufacturer’s instructions.
For every infection, 3–5 mice were sacrificed the following day to
determine the day 1 lung implantation. Lungs were dissected and
homogenized in phosphate buffered saline (PBS). The lung
homogenates were then serially diluted and plated in duplicate on
selective 7H11 agar plates (Becton-Dickinson); plates were incubat-
ed for 3 weeks at 37uC and colonies were counted.
Drug preparation and administration
Trequinsin and MBM were obtained from EMD Millipore
Bioscience. Cilostazol (trade name PletalH) is manufactured by
Otsuka Pharmaceutical Co., and Sildenafil (trade name ViagraH)
is manufactured by Pfizer. Isoniazid and rifampin were obtained
from Sigma-Aldrich, and pyrazinamide was obtained from Fisher
Scientific. Stock solutions were prepared weekly using distilled
water or PBS and stored at 4uC.
All drugs were administered to mice by oral gavage. Drug
solutions were prepared such that the desired concentration would
be delivered in a 0.2 ml total volume. Rifampin was given 1 hour
after administration of other drugs to avoid an adverse
pharmacokinetic interaction [32].
Measurement of intracellular cAMP in THP-1 cells
THP-1 cells were plated at 5610
5 per well in a 6-well cell
culture dish (1 ml/well) and were stimulated with 50 ng/ml of
phorbol 12-myristate 13-acetate; cells were then incubated
overnight at 37uC/5% CO2 to allow for cell attachment.
Trequinsin and MBM were administered at a concentration of
100 mM, and the cells were incubated with the drugs for 2 hours.
Diluted mid-log phase M.tb. strain H37Rv was then added to the
cells to achieve a multiplicity of infection of 1:4. The bacterial
suspension was incubated with the cells at 37uC/5% CO2 for
3 hours, after which the cells were washed and lysed with a
digitonin/Tween-80 lysis buffer. The cAMP concentration in the
cell lysates was determined using the Cyclic AMP Enzyme
Immunoassay Kit (Assay Designs).
Analyses of PDE-I treatment of BALB/c mice
All BALB/c mice were infected by aerosol as described above,
with inocula as detailed in the main text. Treatment regimens
were administered by oral gavage as described above and with
doses as indicated in the main text. At the appropriate time points,
five mice per group were sacrificed using isoflurane vapor. Total
body weight was recorded, and then lungs were dissected and
weighed. The lungs were kept in PBS for 24 hours at 4uC, and
then examined for gross pathology. Lung samples were preserved
in 10% formalin fixative for histopathology analyses, and the
remaining lung was homogenized in PBS, serially diluted and
plated on selective 7H11 agar plates. CFUs were counted after 3
weeks of incubation at 37uC.
Analyses of PDE-I treatment of C3HeB/FeJ mice
C3HeB/FeJ mice were either not infected or infected with 3.67
log10CFU by aerosol as described above. Drug treatment was
initiated the day after infection and was administered as described
above. At the indicated time points, five mice per group were
sacrificed using isoflurane vapor. Total body weight was recorded,
and the lungs were dissected and weighed. Immediately following
dissection, the lungs were homogenized in PBS, and then
aliquotted for CFU determination (performed as described above
for BALB/c mice) and cytokine measurement. Lung homogenates
were stored at 280uC until the experiment was completed, and
then all samples were analyzed in duplicate for cytokine levels
using the Milliplex MAP mouse cytokine/chemokine kit (Millipore),
and the samples were run on a Bio-plex system (Bio-Rad).
Data Analysis
Lung or spleen CFU counts (x) were log-transformed as log10
(x+1) before analysis (means and standard deviations). The Student
t-test, Bonferroni’s Multiple Comparison Test or Kaplan Meier
test were used. A p-value of 0.05 was considered significant for all
statistical analyses.
Supporting Information
Figure S1 Log10 mean CFU evolutions of C3HeB/FeJ
mice. C3HeB/FeJ mice uninfected or aerosol infected with 3.67
log10 CFUs of M. tuberculosis CDC1551 on Day1 were treated daily
(5/7 days/week) with 10 mg/kg of Cilostazol or Sildenafil (5 mice
per group and per time point: D-3, D-10 and D-25). The CFUs
evolution is shown for infected mice during treatment.
(TIFF)
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